Insider · CIK 0001848205

Greenway Schond L.

Reports to the SEC for 2 companies · ROCKVILLE, MD

sec.gov

Transactions

Companies

Filings

CIK

0001848205

Forms 4 and 5

Insider transactions

17 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-03-25	DFTXDefinium Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−5,560 sh	$9.78	−$54.4K	211,057
2024-02-27	DFTXDefinium Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+150K sh	—	—	150,000
2023-12-26	DFTXDefinium Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,652 sh	$3.63	−$20.5K	216,617
2023-09-25	DFTXDefinium Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,908 sh	$3.57	−$6,811.56	226,123
2023-09-25	DFTXDefinium Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,854 sh	$3.58	−$13.8K	222,269
2023-08-25	DFTXDefinium Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−20K sh	$3.80	−$76K	228,031
2023-06-27	DFTXDefinium Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−7,694 sh	$3.19	−$24.5K	251,972
2023-06-27	DFTXDefinium Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,941 sh	$3.21	−$12.7K	248,031
2023-03-14	DFTXDefinium Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+175K sh	—	—	1,445,000
2023-03-14	DFTXDefinium Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+175K sh	—	—	259,666
2022-05-23	DFTXDefinium Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+1.27M sh	—	—	1,270,000
2022-05-23	DFTXDefinium Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+1.65M sh	—	—	1,650,000
2022-05-23	DFTXDefinium Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+1.27M sh	—	—	1,270,000
2022-05-23	DFTXDefinium Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+1.65M sh	—	—	1,650,000
2021-12-10	AVTXAvalo Therapeutics, Inc.P Purchase	CFO	PPurchase	+2,231 sh	$1.57	+$3,502.67	3,883
2021-06-10	AVTXAvalo Therapeutics, Inc.P Purchase	CFO	PPurchase	+652 sh	$2.68	+$1,747.36	1,652
2021-03-01	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	CFO	AAward	+500K sh	—	—	500,000

Recent filings

Accepted (ET)
Mar 264
Greenway Schond L.0000950170-24-036578
SEC(opens sec.gov)
Feb 294
Greenway Schond L.0000950170-24-023204
SEC(opens sec.gov)
Dec 264
Greenway Schond L.0000950170-23-073063
SEC(opens sec.gov)
Sep 254
Greenway Schond L.0000950170-23-049777
SEC(opens sec.gov)
Aug 284
Greenway Schond L.0000950170-23-044853
SEC(opens sec.gov)
Jun 274
Greenway Schond L.0000950170-23-030242
SEC(opens sec.gov)
Apr 244/A
Greenway Schond L.0001209191-23-025476
SEC(opens sec.gov)
Mar 174
Greenway Schond L.0001209191-23-019890
SEC(opens sec.gov)
Jun 34/A
Greenway Schond L.0001209191-22-033984
SEC(opens sec.gov)
May 234
Greenway Schond L.0001209191-22-031402
SEC(opens sec.gov)
Dec 144
Greenway Schond L.0001879785-21-000035
SEC(opens sec.gov)
Jun 144
Greenway Schond L.0001192482-21-000500
SEC(opens sec.gov)
Mar 14
Greenway Schond L.0001192482-21-000194
SEC(opens sec.gov)

Companies

Address

C/O AVALO THERAPEUTICS, INC. 540 GAITHER ROAD, SUITE 400

ROCKVILLE, MD, 20850